TY - JOUR
T1 - Novel cell line development strategy for monoclonal antibody manufacturing using translational enhancing technology
AU - Masuda, Kenji
AU - Watanabe, Kazuhiko
AU - Ueno, Tomonori
AU - Nakazawa, Yuto
AU - Tanabe, Yumiko
AU - Ushiki-Kaku, Yuko
AU - Ogawa-Goto, Kiyoko
AU - Ehara, Yukikazu
AU - Saeki, Hisashi
AU - Okumura, Takeshi
AU - Nonaka, Koichi
AU - Kamihira, Masamichi
N1 - Funding Information:
This study was partially supported by the developing key technologies for discovering and manufacturing pharmaceuticals used for next-generation treatments and diagnoses, both from the Ministry of Economy, Trade and Industry (METI), Japan , and from the Japan Agency for Medical Research and Development (AMED) ( JP17ae0101003 ).
Publisher Copyright:
© 2021 The Society for Biotechnology, Japan
PY - 2022/3
Y1 - 2022/3
N2 - Chinese hamster ovary (CHO) cells are widely used for constructing expression systems to produce therapeutic proteins. However, the establishment of high-producer clones remains a laborious and time-consuming process, despite various progresses having been made in cell line development. We previously developed a new strategy for screening high monoclonal antibody (mAb)-producing cells using flow cytometry (FCM). We also reported that p180 and SF3b4 play key roles in active translation on the endoplasmic reticulum, and that the productivity of secreted alkaline phosphatase was enhanced by the overexpression of p180 and SF3b4. Here, we attempted to apply the translational enhancing technology to high mAb-producing cells obtained after high-producer cell sorting. A high mAb-producing CHO clone, L003, which showed an mAb production level of >3 g/L in fed-batch culture, was established from a high mAb-producing cell pool fractionated by FCM. Clones generated by the overexpression of p180 and SF3b4 in L003 cells were evaluated by fed-batch culture. The specific productivity of clones overexpressing these two factors was ∼3.1-fold higher than that of parental L003 cells in the early phase of the culture period. Furthermore, the final mAb concentration was increased to 9.5 g/L during 17 days of fed-batch culture after optimizing the medium and culture process. These results indicate that the overexpression of p180 and SF3b4 would be promising for establishing high-producer cell lines applicable to industrial production.
AB - Chinese hamster ovary (CHO) cells are widely used for constructing expression systems to produce therapeutic proteins. However, the establishment of high-producer clones remains a laborious and time-consuming process, despite various progresses having been made in cell line development. We previously developed a new strategy for screening high monoclonal antibody (mAb)-producing cells using flow cytometry (FCM). We also reported that p180 and SF3b4 play key roles in active translation on the endoplasmic reticulum, and that the productivity of secreted alkaline phosphatase was enhanced by the overexpression of p180 and SF3b4. Here, we attempted to apply the translational enhancing technology to high mAb-producing cells obtained after high-producer cell sorting. A high mAb-producing CHO clone, L003, which showed an mAb production level of >3 g/L in fed-batch culture, was established from a high mAb-producing cell pool fractionated by FCM. Clones generated by the overexpression of p180 and SF3b4 in L003 cells were evaluated by fed-batch culture. The specific productivity of clones overexpressing these two factors was ∼3.1-fold higher than that of parental L003 cells in the early phase of the culture period. Furthermore, the final mAb concentration was increased to 9.5 g/L during 17 days of fed-batch culture after optimizing the medium and culture process. These results indicate that the overexpression of p180 and SF3b4 would be promising for establishing high-producer cell lines applicable to industrial production.
UR - http://www.scopus.com/inward/record.url?scp=85121389515&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121389515&partnerID=8YFLogxK
U2 - 10.1016/j.jbiosc.2021.11.010
DO - 10.1016/j.jbiosc.2021.11.010
M3 - Article
C2 - 34930670
AN - SCOPUS:85121389515
SN - 1389-1723
VL - 133
SP - 273
EP - 280
JO - Journal of Bioscience and Bioengineering
JF - Journal of Bioscience and Bioengineering
IS - 3
ER -